MedTrace Logo

Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee

NCT00819572 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2010-09-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether an intra-articular injection of DLX105 to the knee joint of patients suffering from severly painful osteoarthritis is safe and reduces pain.

Conditions

Interventions

BIOLOGICAL

DLX105, a single-chain (scFv) antibody fragment against TNF-alpha

Comparison of two different doses of intra-articular DLX105

DRUG

Placebo

Sponsors & Collaborators

  • ESBATech AG

    lead INDUSTRY

Principal Investigators

  • Prof. Georg Schett, MD · University Hospital of Erlangen, Germany

  • Prof. Hansjörg Häuselmann, MD · Rheumazentrum, Zurich Switzerland (Country Coordinator)

  • PD.Dr. Diego Kyburz, MD · University Hospital Zurich, Switzerland (Country Coordinator)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819572 on ClinicalTrials.gov